CMPS - Compass Pathways Plc

5.73
-0.150   -2.618%

Share volume: 2,642,057
Last Updated: 03-19-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$5.88
-0.15
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 28%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.19%
1 Month
-28.82%
3 Months
-12.25%
6 Months
13.69%
1 Year
93.25%
2 Year
-41.41%
Key data
Stock price
$5.73
P/E Ratio 
0.00
DAY RANGE
$5.57 - $5.83
EPS 
$556.76
52 WEEK RANGE
$2.25 - $8.90
52 WEEK CHANGE
$84.84
MARKET CAP 
549.743 M
YIELD 
N/A
SHARES OUTSTANDING 
96.017 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,483,849
AVERAGE 30 VOLUME 
$3,782,042
Company detail
CEO: Kabir K. Nath
Region: US
Website: compasspathways.com
Employees: 120
IPO year: 2020
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression. The company was formerly known as COMPASS Rx Limited.

Recent news